. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012 Jul;11(7):597-604. Epub 2012 Jun 6 PubMed.

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Slow and Steady—Active Immunization Crawls Toward Promise